3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Classical hematology
1
Conditions
Venous Thromboembolism
1
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Hemorrhage
1
Interventions
fludarabine phosphate
29
ruxolitinib
28
Peripheral Blood Stem Cell Transplantation
26
Cyclophosphamide
25
Busulfan
21
Tacrolimus
16
Whole-Body Irradiation
15
Mycophenolic Acid
14
Methotrexate
13
Cyclosporine
12
Hydroxyurea
11
Antilymphocyte Serum
11
Aspirin
9
fludarabine
8
Filgrastim
8
Melphalan
7
Etoposide
7
Decitabine
7
peginterferon alfa-2a
6
Imatinib Mesylate
6
Cytarabine
6
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
6
givinostat hydrochloride
5
givinostat
5
Radiotherapy
5
Prednisone
5
Carboplatin
5
Biopsy
5
Topotecan
4
Thiotepa
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Polycythemia Vera
×
N(4)-oleylcytosine arabinoside
×
Myeloid
×
Clear all
NCT05198960
2026-03-20
AVAJAK
University Hospital, Brest
Phase 3
Recruiting
1,308 enrolled